KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Enterprise Value (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Enterprise Value for 15 consecutive years, with -$308.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 31.95% to -$308.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$308.7 million, a 31.95% increase, with the full-year FY2025 number at -$308.7 million, up 31.95% from a year prior.
  • Enterprise Value was -$308.7 million for Q4 2025 at Supernus Pharmaceuticals, down from -$281.2 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$151.7 million in Q2 2023 to a low of -$522.6 million in Q2 2025.
  • A 5-year average of -$351.2 million and a median of -$354.0 million in 2022 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: skyrocketed 57.97% in 2023, then plummeted 128.93% in 2024.
  • Supernus Pharmaceuticals' Enterprise Value stood at -$339.7 million in 2021, then crashed by 35.81% to -$461.3 million in 2022, then surged by 44.75% to -$254.9 million in 2023, then tumbled by 77.97% to -$453.6 million in 2024, then skyrocketed by 31.95% to -$308.7 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Enterprise Value are -$308.7 million (Q4 2025), -$281.2 million (Q3 2025), and -$522.6 million (Q2 2025).